| 发明名称 | Use of mutant Herpes Simplex Virus-2 for cancer therapy | ||
| 摘要 | The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP 10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity. | ||
| 申请公布号 | US8986672(B2) | 申请公布日期 | 2015.03.24 |
| 申请号 | US200611922796 | 申请日期 | 2006.06.23 |
| 申请人 | The University Of Houston | 发明人 | Zhang Xiaoliu;Xinping Fu |
| 分类号 | A01N63/00;A61K48/00;C12N7/01;C12N15/63;C07K14/005;C12N7/00;C12N15/86;A61K38/17;A61K38/00 | 主分类号 | A01N63/00 |
| 代理机构 | Wong, Cabello, Lutsch, Rutherford & Brucculeri, LLP | 代理人 | Wong, Cabello, Lutsch, Rutherford & Brucculeri, LLP |
| 主权项 | 1. A method of selectively killing cancer cells in a subject in need thereof, the method comprising: intratumorally or systemically administering to the subject in need thereof an effective amount of a fusogenic mutant Herpes Simplex Virus Type 2 (HSV-2), wherein the fusogenic mutant HSV-2 comprises a modified ICP10 coding region lacking nucleotides 1 to 1204 of an endogenous ICP10 coding region, wherein said fusogenic mutant HSV-2 comprises the modified ICP10 operably linked to an endogenous or a constitutive promoter and expresses a modified ICP10 polypeptide that lacks protein kinase (PK) activity but retains ribonucleotide reductase activity, and wherein said administration provides for selective killing of cancer cells by direct cytolysis and syncytia formation in cells that are susceptible to replication of the fusogenic mutant HSV-2. | ||
| 地址 | Houston TX US | ||